Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
DAD-IO
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04724018 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Deep
We haven't built an HCP commentary report on DAD-IO (sacituzumab govitecan, enfortumab vedotin-ejfv and 1 more in Urothelial Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DAD-IO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 20 | |
| YouTube | 7 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder Cancer
- Interventions
- Sacituzumab Govitecan (SG); Enfortumab vedotin-ejfv (EV); Pembrolizumab
- Arms
- Dose Escalation Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) · Experimental
- Dose Expansion Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) · Experimental
- Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) and Pembrolizumab · Experimental
- Enrollment
- 106 (estimated)
- Primary outcomes
- Maximum Tolerated Dose (MTD) of Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) in Combination
- Dose-limiting toxicity (DLT) of Sacituzumab Govitecan (SG) and Enfortumab Vedotin in combination
- Efficacy of Sacituzumab Govitecan (SG) and Enfortumab Vedotin in combination
- Efficacy of Sacituzumab Govitecan (SG) and Enfortumab Vedotin and Pembrolizumab in combination
- Sponsor
- Dana-Farber Cancer Institute with Gilead Sciences
- Start
- May 20, 2021
- Primary completion
- Feb 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04724018 · updated Nov 4, 2025
Publications
linked from the registry- McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21. PubMed 37871703